Managed Entry Agreements (MEAs) are important tools for reimbursement across Sweden, Norway, Denmark, and Finland – especially in areas such as oncology, rare diseases and precision medicine. While their use is growing, the pathways and requirements differ substantially between countries.
From what we’re seeing at Quantify:
â–  The road to MEAs differs in each country, for instance:
➡️ In Sweden and Finland, for outpatient medicines, companies may propose MEAs during the reimbursement process, but it is not their decision whether a net price will be discussed – proposals are made upfront to TLV in Sweden and after the first Hila Board meeting in Finland if criteria are met.
➡️ In Denmark and Norway, for medicines under the DMC and New Methods routes, net price negotiations and MEA proposals are built into the process, as they are for hospital medicines under the NT Council and Fimea routes in Sweden and Finland.
➡️ At the same time in Denmark, in case of an alternative contract model, a dedicated form must be submitted together with the assessment request.

Negotiations and agreement processes now tend to take longer, likely reflecting the growing complexity of MEAs.

■ Cross-border collaboration is picking up, with JNHB likely becoming a more established pathway for reimbursement discussions and joint negotiations in the future.

At Quantify, we help clients untangle these differences and design access strategies that fit the policy and payer requirements in each market.

Are you working with MEAs in the Nordics? We’d love to hear how it’s playing out in your experience.